HER2-Positive Breast Carcinoma — Trials

HER2-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 140
Recruiting: 73
Ph III recruiting: 15
Growth YoY: +11.5%
Industry share: 19%
Top sponsor: Fudan University
Termination share: 43.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 51–61 of 61 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04034823	KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer	unknown	Phase 2	59	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER	0	Jul 26, 2019	clinicaltrials
NCT04033172	Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )(Pyrotinib)	unknown	Phase 2	40	Chinese Academy of Medical SciencesOTHER	1	Jul 25, 2019